A
17.67
0.22 (1.26%)
| Previous Close | 17.45 |
| Open | 17.24 |
| Volume | 2,440,056 |
| Avg. Volume (3M) | 2,511,177 |
| Market Cap | 2,220,801,024 |
| Price / Sales | 2.93 |
| Price / Book | 13.98 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -28.83% |
| Operating Margin (TTM) | -49.96% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | -3.20% |
| Total Debt/Equity (MRQ) | 285.94% |
| Current Ratio (MRQ) | 4.08 |
| Operating Cash Flow (TTM) | -8.29 M |
| Levered Free Cash Flow (TTM) | 45.63 M |
| Return on Assets (TTM) | -14.20% |
| Return on Equity (TTM) | -103.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Apellis Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.77% |
| % Held by Institutions | 104.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Raymond James, 194.28%) | Buy |
| Median | 29.00 (64.12%) | |
| Low | 18.00 (RBC Capital, 1.87%) | Hold |
| Average | 31.73 (79.57%) | |
| Total | 5 Buy, 6 Hold | |
| Avg. Price @ Call | 17.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 02 Jul 2025 | 26.00 (47.14%) | Hold | 17.82 |
| Wells Fargo | 02 Jun 2025 | 29.00 (64.12%) | Hold | 19.14 |
| 08 May 2025 | 26.00 (47.14%) | Hold | 17.81 | |
| Citigroup | 22 May 2025 | 41.00 (132.03%) | Buy | 17.78 |
| Mizuho | 14 May 2025 | 20.00 (13.19%) | Hold | 16.70 |
| B of A Securities | 09 May 2025 | 23.00 (30.16%) | Hold | 17.30 |
| Raymond James | 09 May 2025 | 52.00 (194.28%) | Buy | 17.30 |
| Baird | 08 May 2025 | 47.00 (165.99%) | Buy | 17.81 |
| RBC Capital | 08 May 2025 | 18.00 (1.87%) | Hold | 17.81 |
| 21 Apr 2025 | 21.00 (18.85%) | Hold | 18.03 | |
| Scotiabank | 08 May 2025 | 20.00 (13.19%) | Hold | 17.81 |
| Needham | 07 May 2025 | 29.00 (64.12%) | Buy | 17.99 |
| Cantor Fitzgerald | 29 Apr 2025 | 44.00 (149.01%) | Buy | 18.21 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) |
| 06 Jun 2025 | Announcement | Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN |
| 04 Jun 2025 | Announcement | Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference |
| 07 May 2025 | Announcement | Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results |
| 06 May 2025 | Announcement | Apellis Pharmaceuticals to Present at Upcoming Investor Conferences |
| 30 Apr 2025 | Announcement | Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results |
| 21 Apr 2025 | Announcement | Apellis Announces Craig Wheeler to Join the Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |